Clinical Report: Successful Treatment of Primary Plasma Cell Leukemia

Overview

This report details a case of primary plasma cell leukemia (pPCL) treated with sequential allogeneic hematopoietic stem cell transplantation following combination chemotherapy.

Background

Primary plasma cell leukemia (pPCL) is a rare and aggressive form of plasma cell neoplasm characterized by a poor prognosis and a median overall survival of less than one year. The treatment landscape for pPCL remains controversial due to its low incidence and the challenges in achieving long-term survival with conventional therapies.

Data Highlights

No numerical data or trial data presented in the article.

Key Findings

• pPCL is characterized by acute onset, short disease course, and poor prognosis.
• The IMWG updated diagnostic criteria for pPCL to include patients with 5-19% circulating plasma cells.
• Combination chemotherapy followed by allogeneic hematopoietic stem cell transplantation may offer a treatment approach for pPCL.
• The patient in this case study achieved disease-free survival after treatment.
• Conventional treatments for pPCL have historically resulted in limited long-term survival.

Clinical Implications

Clinicians should consider sequential treatment approaches, including allogeneic hematopoietic stem cell transplantation, for patients with pPCL.

Conclusion

The treatment of pPCL in this case highlights the need for further investigation into sequential therapies.

Related Resources & Content

1. European Myeloma Network Group, 2021 -- Review and Consensus Statement on Primary Plasma Cell Leukemia
2. Outcomes of hematopoietic stem cell transplantation in primary plasma cell leukemia: A systematic review and meta-analysis, ScienceDirect, 2024
3. The ASCO Post — Study Explores When to Proceed to Stem Cell Transplantation for Patients With Resistant AML
4. Bone Marrow Transplantation — Allogeneic Hematopoietic Stem Cell Transplantation as a Potentially Curative Option for AML Patients Failing to Achieve Remission
5. Blood Cancer Journal — The Role of Anti-Thymocyte Globulin in Enhancing Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Aggressive T-Cell Neoplasms
6. Bone Marrow Transplantation — Successful Treatment of Central Nervous System Intravascular NK/T-cell Lymphoma with Allogeneic Hematopoietic Stem Cell Transplantation
7. Study Explores When to Proceed to Stem Cell Transplantation for Patients With Resistant AML
8. Allogeneic Hematopoietic Stem Cell Transplantation as a Potentially Curative Option for AML Patients Failing to Achieve Remission
9. The Role of Anti-Thymocyte Globulin in Enhancing Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Aggressive T-Cell Neoplasms
10. https://pure.eur.nl/ws/portalfiles/portal/186412827/European_Myeloma_Network_Group_review_and_consensus_statement_on_primary_plasma_cell_leukemia.pdf
11. Outcomes of hematopoietic stem cell transplantation in primary plasma cell leukemia: A systematic review and meta-analysis - ScienceDirect
12. Outcomes of pPCL Diagnosed Using the IMWG 2021 Consensus Definition: A Retrospective Multicenter Analysis
13. Outcomes and treatment patterns in primary and secondary plasma cell leukemia: insights from a large US cohort study - ScienceDirect